Results 91 to 100 of about 4,091 (198)
The iPSC Awakens ANGPTL3 in Tangier Disease [PDF]
Man K.S. Lee, Andrew J. Murphy
openaire +3 more sources
Background: Angiopoietin-like protein 3 (ANGPTL3), a member of angiopoietin-like proteins, has been demonstrated to affect lipid metabolism by inhibiting the activity of lipoprotein lipase (LPL).
Liu, ZY +5 more
core +2 more sources
Białka podobne do angiopoetyny (ANGPTL) tworzą rodzinę kilku białek, z których ANGPTL3, 4 i 8 są zaangażowane w metabolizm lipidów. Białka te, odkryte stosunkowo niedawno, regulują dostępność triglicerydów dla serca, mięśni szkieletowych oraz białej i ...
Surma, Stanisław; Wydział Nauk Medycznych w Katowicach, Śląski Uniwersytet Medyczny w Katowicach, Medyków 18, 40-752 Katowice, Poland +2 more
core
Minh Hoang Thi,1 Chung Dang Thanh,2 Thuan Huynh Quang3 1Department of Pathophysiology, Vietnam Military Medical University (VMMU), Ha Noi City, Vietnam; 2Department of Pathology and Forensic Medicine, 103 Military Medical Hospital, Vietnam Military ...
Hoang Thi M, Dang Thanh C, Huynh Quang T
doaj
ANGPTL3 facilitates lipolysis through insulin-resistance development in 3T3-L1 cells.
Detection of loss-of-function (LOF) mutations in ANGPTL3 gene in humans revealed the existence of a new lipid phenotype, called familial combined hypolipidemia (FHBL2) and characterized by markedly reduced levels of all lipoproteins.
L. Polito, A. Ghadiri, M. Arca
core
In Silico Description of the Direct Inhibition Mechanism of Endothelial Lipase by ANGPTL3 [PDF]
Angiopoietin-like protein 3 (ANGPTL3) is a plasmatic protein that plays a crucial role in lipoprotein metabolism by inhibiting the lipoprotein lipase (LPL) and the endothelial lipase (EL) responsible for the hydrolysis of phospholipids on high-density ...
L. Palazzolo +17 more
core +1 more source
Abstracts of the 18th SCWD Conference, 11‐13 December 2025 in Rome/Italy
JCSM Communications, Volume 9, Issue 1, January/June 2026.
wiley +1 more source
Despite observations of decreased ANGPTL3 (angiopoietin-like protein 3) levels in tubular atrophy and renal interstitial fibrosis (RIF), its functional implications and regulatory mechanisms in RIF remain unclear.
Bin Yang +3 more
doaj +1 more source
Background. Diabetes mellitus is often accompanied by dyslipidemia. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, as a novel therapeutic agent for the treatment of type 2 diabetes mellitus (T2DM), have been reported to exert effects on lipid, while ...
Simo Liu +6 more
doaj +1 more source

